View source for NNC9204-1706

{{Orphan|date=August 2024}}
'''NNC9204-1706'''  or '''NN9423''' is a GLP-1/GIP/glucagon receptor triple agonist developed by [[Novo Nordisk]].<ref>{{cite journal |last1=Jepsen |first1=Mathies M. |last2=Christensen |first2=Mikkel B. |title=Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity |journal=Expert Opinion on Emerging Drugs |date=September 2021 |volume=26 |issue=3 |pages=231–243 |doi=10.1080/14728214.2021.1947240 |pmid=34176426 |s2cid=235661514 |url=https://pubmed.ncbi.nlm.nih.gov/34176426/ |issn=1744-7623}}</ref><ref>{{cite journal |last1=Bergmann |first1=Natasha Chidekel |last2=Davies |first2=Melanie J. |last3=Lingvay |first3=Ildiko |last4=Knop |first4=Filip K. |title=Semaglutide for the treatment of overweight and obesity: A review |journal=Diabetes, Obesity and Metabolism |date=January 2023 |volume=25 |issue=1 |pages=18–35 |doi=10.1111/dom.14863 |pmid=36254579 |pmc=10092086 |language=en |issn=1462-8902}}</ref> It was evaluated in a clinical trial;<ref>{{cite journal |last1=Abdi Beshir |first1=Semira |last2=Ahmed Elnour |first2=Asim |last3=Soorya |first3=Aadith |last4=Parveen Mohamed |first4=Affana |last5=Sir Loon Goh |first5=Sheron |last6=Hussain |first6=Nadia |last7=Al Haddad |first7=Amal H. I. |last8=Hussain |first8=Faizah |last9=Yousif Khidir |first9=Israa |last10=Abdelnassir |first10=Zainab |title=A narrative review of approved and emerging anti-obesity medications |journal=Saudi Pharmaceutical Journal |date=1 October 2023 |volume=31 |issue=10 |pages=101757 |doi=10.1016/j.jsps.2023.101757 |pmid=37712012 |pmc=10497995 |issn=1319-0164}}</ref><ref>{{cite journal |last1=Müller |first1=Timo D. |last2=Blüher |first2=Matthias |last3=Tschöp |first3=Matthias H. |last4=DiMarchi |first4=Richard D. |title=Anti-obesity drug discovery: advances and challenges |journal=Nature Reviews. Drug Discovery |date=2022 |volume=21 |issue=3 |pages=201–223 |doi=10.1038/s41573-021-00337-8 |pmid=34815532 |pmc=8609996 |issn=1474-1776}}</ref> adverse effects such as "dose-dependent increases in [[heart rate]] and reductions in [[reticulocyte]] count, increases in markers of inflammation and hepatic disturbances, and impaired [[glucose tolerance]] at the highest dosages" meant that the drug was declared to have an inadequate safety profile and discontinued.<ref name=Peptides2023>{{cite journal |last1=Novikoff |first1=Aaron |last2=Müller |first2=Timo D. |title=The molecular pharmacology of glucagon agonists in diabetes and obesity |journal=Peptides |date=2023 |volume=165 |pages=171003 |doi=10.1016/j.peptides.2023.171003 |issn=0196-9781|doi-access=free |pmid=36997003 |pmc=10265134 }}</ref>
==References==
{{reflist}}
[[Category:GLP-1 receptor agonists]]
[[Category:Peptide therapeutics]]
[[Category:GIP receptor agonists]]
[[Category:Glucagon receptor agonists]]
[[Category:Abandoned drugs]]